PIM
TRDA icon

Plato Investment Management’s Entrada Therapeutics TRDA Stock Holding History

Plato Investment Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-61
Closed -$869 – 573
2024
Q2 		$869 Sell
61
-1,055
-95% -$15K ﹤0.01% 493
2024
Q1 		$15.8K Hold
1,116
– – ﹤0.01% 421
2023
Q4 		$16.8K Buy
+1,116
New +$16.5K 0.02% 328

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Plato Investment Management's TRDA Position: Q3 2024 in Review

Plato Investment Management sold out of Entrada Therapeutics (TRDA) in Q3 2024, closing a stake of 61 shares — an estimated $869 sold.

Plato Investment Management first reported a position in TRDA in Q4 2023 and held it in 3 quarters. The position peaked at $16.8K in Q4 2023. 97 funds tracked by Wall St. Rank hold TRDA as of Q3 2024.

  • Plato Investment Management reported no remaining Entrada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Plato Investment Management sold 61 Entrada Therapeutics shares in Q3 2024, an estimated $869.
  • Plato Investment Management first reported a position in Entrada Therapeutics in Q4 2023 and held it in 3 quarters.
  • Plato Investment Management's Entrada Therapeutics position peaked at $16.8K in Q4 2023.
  • 97 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2024.

Based on Plato Investment Management's 13F filing for Q3 2024, filed 6 Nov 2024.